CASI missed EPS expectations by 1292.16%
May 27, 2024, 4:31 PM
12.46%
What does CASI do
CASI Pharmaceuticals, headquartered in Beijing, focuses on developing and commercializing therapeutics, with a particular emphasis on hematology oncology and other medical needs worldwide. The company, which went public in 2021, markets products like EVOMELA in the U.S. and has several pipeline products and FDA-approved generics for the China market.
CASI Pharmaceuticals Inc (CASI) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, CASI Pharmaceuticals Inc's actual EPS was -$0.71, missing the estimate of -$0.05 per share, resulting in a -1292.16% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.